Everest in the Alps: the second ascent

Thirty inspirational challengers, seven teams, one epic goal. To ski the height of Everest over four consecutive days and raise vital funds for research into paediatric brain tumours.

The intrepid skiers travelled to the alpine village of Verbier in Switzerland and had to battle atrocious conditions to complete the 8,848m climb.

The group has already smashed their original fundraising target and is on course to raise more than £1m – an amount that will make a huge impact in our mission to find a cure faster.

The funds will support the work of the Everest Centre, a pan- European collaboration of scientists established last year to improve the understanding and treatment of childhood brain tumours.

The story behind the challenge

The gruelling climb was inspired by our trustee Rob Ritchie - who scaled the same heights three years earlier with a group of friends and family.

Rob was motivated after getting the shocking news that his five-year-old son Toby had a low-grade tumour and has vowed to help speed up the search for a cure.

Sadly Toby is not an isolated case. Globally, over 26,870 children and young adults have a paediatric low grade (slower growing) brain tumour. And every day a young person takes another step in dealing with their own personal Everest.

Donate to the teams

You can still help the Everest in the Alps: the second ascent teams by donating to their JustGiving.

We're delighted to be partnering with A Kid's Brain Tumour Cure in New York. For more information or if you're an American citizen and would like to donate, please visit their website.


Donate to the brave teams who completed Everest in the Alps: the second ascent.

The Everest Centre

Everest in the Alps funds ground-breaking research into paediatric low grade tumours.

Latest news

With donations still coming in, the expeditions is expected to exceed the £1million mark.

We promise to keep your data safe and you can unsubscribe at any time in the future. More information is in our Privacy Policy.